VAD chemotherapy as remission induction for multiple myeloma
Open Access
- 1 February 1995
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 71 (2), 326-330
- https://doi.org/10.1038/bjc.1995.65
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- SDZ PSC-833—a novel potent in vitro chemosensitizer in multiple myelomaAnti-Cancer Drugs, 1992
- Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot studyBritish Journal of Haematology, 1992
- Multiple myeloma: Intensified maintenance therapy with recombinant interferon‐α‐2b plus glucocorticoidsEuropean Journal of Haematology, 1992
- Combination of interferon and dexamethasone in refractory multiple myelomaHematological Oncology, 1990
- Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction ChemotherapyNew England Journal of Medicine, 1990
- INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSIONThe Lancet, 1989
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Treatment of multiple myelomaCancer Treatment Reviews, 1981